KDA Group Inc. announced an agreement with ZoomMed Inc. whereby KDA Group can distribute under a non-exclusive license the ZRx Prescriber developed by ZoomMed in the United States. The Corporation and ZoomMed are also expecting to conclude, shortly, a joint venture agreement in order to unite their expertise for the development and commercialization of the ZRx Prescriber in the US market. KDA Group and ZoomMed are arms' length parties.

KDA Group will issue ZoomMed 10,000,000 common class A shares of its share capital at a deemed value of CAD 1,720,000, based on the average closing price of the Common Shares for the last 52 weeks to April 30, 2018, being CAD 0.172 per common share. In addition, ZoomMed will be entitled to receive royalties, up to USD 2,500,000 under certain terms and conditions. The Common Shares will be subject to a four month and one day mandatory holding period.